Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-19T03:51:37.758Z Has data issue: false hasContentIssue false
  • English
  • Français

High-dose enoxaparin in the treatment of abdominal angiostrongyliasis in Swiss mice

Published online by Cambridge University Press:  03 October 2017

A.S.S. Sandri ,
R. Rodriguez ,
M.M. Costa ,
S.M. Porto ,
D. Schwingel  and
M.I.B. Vieira
A.S.S. Sandri
Affiliation:
Graduate Program in Bioexperimentation, Universidade de Passo Fundo, Passo Fundo, RS, Brazil
R. Rodriguez
Affiliation:
Universidade de Passo Fundo – UPF, Passo Fundo, RS, Brazil
M.M. Costa
Affiliation:
Universidade de Passo Fundo – UPF, Passo Fundo, RS, Brazil
S.M. Porto
Affiliation:
Universidade de Passo Fundo – UPF, Passo Fundo, RS, Brazil
D. Schwingel
Affiliation:
Graduate Program in Bioexperimentation, Universidade de Passo Fundo, Passo Fundo, RS, Brazil
M.I.B. Vieira*
Affiliation:
Graduate Program in Bioexperimentation, Universidade de Passo Fundo, Passo Fundo, RS, Brazil
*
Author for correspondence: M.I.B. Vieira, E-mail: marisabel@upf.br
Get access Rights & Permissions [Opens in a new window]

Abstract

Abdominal angiostrongyliasis (AA) is caused by Angiostrongylus costaricensis, which inhabits mesenteric arteries. There is no drug treatment for AA, and since intestinal infarction due to thrombi is one of the main complications of the disease, the use of anticoagulants may be a treatment option. Thus, we aimed to assess the effect of high doses of enoxaparin on the prevention of ischaemic intestinal lesions and on the survival of mice infected with A. costaricensis. Twenty-four mice were infected with L3 of A. costaricensis and divided equally into two groups: Group 1, control treated with placebo, and Group 2, treated daily with enoxaparin (2.5 mg/kg) for 50 days. All mice were subjected to necropsy and histological analysis. The results from gross and microscopic assessments showed no variation in the prevalence of lesions between the groups. An analysis was also performed among survivors and non-survivors, showing that animals that died often presented lesions, such as granulation tissue in the serosa, and intestinal infarction and adhesion. The mortality rate did not vary between the enoxaparin-treated and control groups. Thus, we showed that high doses of enoxaparin have no protective effect against AA, as the survival rates and lesions of mice did not vary between the treated and control groups. Considering that the use of prophylactic doses was also shown to be ineffective in a previous study, we do not recommend the use of enoxaparin for AA treatment.

Type
Research Paper
Information
Journal of Helminthology , Volume 92 , Issue 6 , November 2018 , pp. 662 - 667
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andújar, MA, Matoses, CC, Rodríguez, LFJ and Navarro, RA (2016) Individualización posológica de enoxaparina en un obeso extremo mediante la monitorización del factor anti-Xa. Farmacia Hospitalaria 40, 58–59.Google Scholar
de Azevedo, GV, Rodriguez, R, Porto, SM, Graeff-Teixeira, C and Fornari, F (2011) Elimination of Angiostrongylus costaricensis larvae in feces from experimentally infected Swiss mice: circadian rhythm and correlation with survival. Parasitology Research 108, 537–540.Google Scholar
Fante, CA, Dieterish, S and Rodriguez, R (2008) Betametasona e extrato aquoso de Arctium lappa no tratamento da angiostrongilíase. Revista da Sociedade Brasileira de Medicina Tropical 41, 654–657.Google Scholar
Graeff-Teixeira, C, Camillo-Coura, L and Lenzi, HL (1991) Histopathological criteria for the diagnosis of abdominal angiostrongyliasis. Parasitology Research 77, 606–611.Google Scholar
Harter, K, Levine, M and Henderson, SO (2015) Anticoagulation drug therapy: a review. Western Journal of Emergency Medicine 16, 11–17.Google Scholar
Ishii, A, Terada, M, Fujiu, Y and Sano, M (1989) In vivo efficacy of levamisole against larval stages of Angiostrongylus cantonensis and A. costaricensis. Southeast Asian Journal of Tropical Medicine and Public Health 20, 109–117.Google Scholar
Li, D-W, Lee, IS, Sim, J-S, Toida, T, Linhardt, RJ and Kim, YS (2004) Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo. Thrombosis Research 113, 67–73.Google Scholar
Mentz, MB and Graeff-Teixeira, C (2003) Drug trials for treatment of human angiostrongyliasis. Revista do Instituto de Medicina Tropical de São Paulo 45, 179–184.Google Scholar
Morera, P and Bontempo, I (1985) Acción de algunos antihelminticos sobre Angiostrongylus costaricensis. Revista Médica del Hospital Nacional de Niños Dr. Carlos Saenz Herrera 20, 165–174.Google Scholar
Morera, P and Céspedes, R (1971) Angiostrongylus costaricensis n. sp. (Nematoda: Metastrongyloidea), a new lungworm occurring in man in Costa Rica. Revista de Biología Tropical 18, 17.Google Scholar
Mousa, SA (2004) Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases. pp. 35–48 In Mousa, S.A. (Ed.) Anticoagulants, Antiplatelets, and Thrombolytics. Totowa, New Jersey, Humana press.Google Scholar
Rafaluk, C, Gildenhard, M, Mitschke, A, Telschow, A, Schulenburg, H and Joop, G (2015) Rapid evolution of virulence leading to host extinction under host–parasite coevolution. BMC Evolutionary Biology 15, 112.Google Scholar
Rodriguez, R, Porto, SM, dos Santos Ferrari, R, Marcolan, AM, da Silva, ACA, Graeff-Teixeira, C and Fornari, F (2011) Outcomes in mice with abdominal angiostrongyliasis treated with enoxaparin. Parasitology Research 109, 787–792.Google Scholar
Silvain, J, Beygui, F, Barthélémy, O, Pollack, C, Cohen, M, Zeymer, U, Huber, K, Goldstein, P, Cayla, G and Collet, J-P (2012) Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. British Medical Journal 344, e553.Google Scholar
Terada, M, Rodriguez, O, Dharejo, A, Ishii, A and Sano, M (1986) Studies on chemotherapy of parasitic helminths (XXVI). Comparative in vitro effects of various anthelmintics on the motility of Angiostrongylus costaricensis and Angiostrongylus cantonensis. Japanese Journal of Parasitology 35, 365–367.Google Scholar
Waisberg, J, Corsi, CE, Rebelo, MV, Vieira, VTT, Bromberg, SH, dos Santos, PA and Monteiro, R (1999) Jejunal perforation caused by abdominal angiostrongyliasis. Revista do Instituto de Medicina Tropical de São Paulo 41, 325–328.Google Scholar